<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750798</url>
  </required_header>
  <id_info>
    <org_study_id>BWI_2019_05</org_study_id>
    <secondary_id>BWI_2019_05</secondary_id>
    <nct_id>NCT04750798</nct_id>
  </id_info>
  <brief_title>An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias</brief_title>
  <official_title>An Observational Post-marketing Study for Evaluation of Ongoing Safety and Effectiveness of Catheter Mapping and Ablation Using Commercially Approved BWI Medical Devices for the Treatment of Patients With Cardiac Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively collect clinical data evaluating the ongoing&#xD;
      safety and performance during routine-use standard cardiac arrhythmia mapping and/or ablation&#xD;
      procedures while using commercial Biosense Webster Inc. (BWI) medical devices. Data generated&#xD;
      from the study will be used to confirm safety and performance of BWI medical devices in the&#xD;
      marketed phase and to expand the body of evidence on the use of these devices and techniques&#xD;
      in treatment of cardiac arrhythmias.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Primary Adverse Events (PAEs) Related to Device in Scope and/or Study Procedure Within 7 Days of the Initial Study Procedure</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Primary Adverse Events include device or procedure related death, Atrio-Esophageal Fistula, Severe Pulmonary Vein Stenosis, Cardiac Tamponade/ perforation, Thromboembolism, Pericarditis, Stroke/ Cerebrovascular Accident, Transient Ischemic Attach, Phrenic Nerve Paralysis (permanent), Myocardial Infarction ,Major Vascular Access Complication/ Bleeding, Heart Block (permanent).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial Fibrillation (AF): Number of Participants with Isolation of all Targeted Pulmonary Veins</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Number of Participants with isolation (entrance block confirmation) of all targeted pulmonary veins will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SupraVentricular Tachycardia (SVT) (Sinus Nodal Re-entrant Tachycardia, Focal AT, Multifocal AT, AVNRT, Non Re-entrant Junctional Tachycardias): Number of Participants with Non-inducibility of the Targeted Tachycardia Post-ablation</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Number of participants with sinus nodal re-entrant tachycardia, focal atrial tachycardia (AT) multifocal AT, atrioventricular nodal reentry tachycardia (AVNRT), non re-entrant junctional tachycardias with non-inducibility of the targeted tachycardia post-ablation will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SVT (MRAT): Number of Participants with Complete Bidirectional Conduction Block Across the Ablation Line</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Number of participants with Macro Re-entrant Atrial Tachycardia (MRAT) with complete bidirectional conduction block across the ablation line will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SVT (AVRT): Number of Participants with Complete Block of Accessory Pathway</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Number of participants with atrioventricular reentry tachycardia (AVRT) with complete block of accessory pathway will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Device and/or Procedure-Related Serious Adverse Events (Serious Adverse Device Effects [SADEs])</measure>
    <time_frame>Up to 365 Days</time_frame>
    <description>Number of participants with device and/or procedure-related Serious Adverse Events (Serious Adverse Device Effects, SADEs) within 7 days (early-onset), &gt;7-30 days (peri-procedural) and &gt;30 days (late onset) following the initial study procedure will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Device and/or Procedure-Related Non-Serious Adverse Events (Non-Serious Adverse Device Effects [ADEs])</measure>
    <time_frame>Up to 365 Days</time_frame>
    <description>Number of participants with device and/or procedure-related non-serious adverse events (Non-serious adverse device effects [ADEs]) within 7 days (early-onset), &gt; 7-30 Days (peri-procedural) and &gt;30 Days (Late Onset) following the initial study procedure will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF: Number of Participants with Acute Reconnection Among all Targeted Pulmonary Veins (PVs)</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Number of participants with Acute reconnection among all targeted PVs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVT (MRAT): Number of Participants with Non-inducibility of the Targeted Tachycardia Post-ablation</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Number of participants with MRAT with non-inducibility of the targeted tachycardia post-ablation will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVT (AVNRT): Number of Participants with Elimination or Modification of Slow Pathway Conduction</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Number of participants with AVNRT with elimination or modification of slow pathway conduction will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF: Number of Participants with Documented (Symptomatic and Asymptomatic) AF, AT, Atrial Flutter (AFL) Episodes</measure>
    <time_frame>From Day 91 to Day 365 (post-blanking)</time_frame>
    <description>Number of participants with documented (symptomatic and asymptomatic) AF, AT, AFL episodes (episodes greater than or equal to [&gt;=] 30 seconds) post-blanking will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF: Number of Participants with Documented Symptomatic AF, AT, AFL Episodes</measure>
    <time_frame>From Day 91 to Day 365 (post-blanking)</time_frame>
    <description>Number of participants with documented symptomatic AF, AT, AFL episodes (episodes &gt;= 30 seconds) post-blanking will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF: Number of Participants with Repeated Ablation</measure>
    <time_frame>From Day 91 to Day 365 (post-blanking)</time_frame>
    <description>Number of participants with repeated ablation post-blanking will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF: Number of Participants with Repeated Ablation with Pulmonary Vein (PV) Reconnection</measure>
    <time_frame>From Day 91 to Day 365 (post-blanking)</time_frame>
    <description>Number of participants with repeated ablation with PV reconnection post blanking will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF: Change in AF Burden Compared to Baseline for Participants with Continuous Arrhythmia Monitoring</measure>
    <time_frame>Baseline, Day 91 up to Day 365</time_frame>
    <description>AF burden will be measured as the change in the percentage of time that participants will be in AF (symptomatic and asymptomatic) compared to baseline will be calculated. The change in AF burden for the overall study population will be calculated and expressed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVT: Number of Participants with Recurrence of Documented Arrhythmia of the Targeted SVT</measure>
    <time_frame>From Day 1 to Day 365</time_frame>
    <description>Number of participants with recurrence of documented arrhythmia of the targeted SVT (episodes &gt;=30 seconds) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVT: Number of Participants with Documented Arrhythmia of new SVT, not Targeted During Index Procedure</measure>
    <time_frame>From Day 1 to Day 365</time_frame>
    <description>Number of participants with documented arrhythmia of new SVT, not targeted during index procedure will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVT: Number of Participants with Repeated Ablation</measure>
    <time_frame>From Day 1 to Day 365</time_frame>
    <description>Number of participants with repeated ablation will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVT: Change in Study Arrhythmia Burden Compared to Baseline for Participants with Continuous Arrhythmia Monitoring</measure>
    <time_frame>From Day 1 to Day 365</time_frame>
    <description>Study arrhythmia burden will be measured as the change in the percentage of time that participants will be in study arrhythmia (symptomatic and asymptomatic) compared to baseline will be calculated. The change in study arrhythmia for the overall study population will be calculated and expressed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Cardiac Arrhythmias</condition>
  <arm_group>
    <arm_group_label>Participants Diagnosed with Cardiac Arrhythmias</arm_group_label>
    <description>Patients diagnosed with cardiac arrhythmias who are scheduled to undergo an ablation procedure in routine clinical practice for management of their arrhythmia with a BWI therapeutic catheter will be observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BWI Medical Device</intervention_name>
    <description>Participants will be treated with commercially approved BWI medical devices following routine clinical practice. No specific intervention will be observed for this study.</description>
    <arm_group_label>Participants Diagnosed with Cardiac Arrhythmias</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population consists of participants diagnosed with cardiac arrhythmias who are&#xD;
        scheduled to undergo an ablation procedure for management of their arrhythmia with a&#xD;
        per-protocol defined Biosense Webster Inc (BWI) therapeutic catheter.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Diagnosed with paroxysmal or persistent Atrial Fibrillation (AF) or supraventricular&#xD;
             tachycardia (SVT) and scheduled to undergo an ablation procedure for management of&#xD;
             their arrhythmia with a per-protocol defined BW therapeutic catheter&#xD;
&#xD;
          -  Able and willing to comply with all pre-, post- and follow-up testing and requirements&#xD;
             as per hospital standard of care&#xD;
&#xD;
          -  Signed Patient Informed Consent Form (ICF)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Currently participating in an interventional (drug, device, biologic, etc.) clinical&#xD;
             trial&#xD;
&#xD;
          -  Life expectancy of less than 12-months&#xD;
&#xD;
          -  Presenting any contra-indication for the use of BWI Commercially approved medical&#xD;
             devices, as indicated in the respective IFU or User Manuals&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biosense Webster, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Biosense Webster, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Macours</last_name>
    <phone>+32 479 97 05 05</phone>
    <email>nmacours1@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ordensklinikum Linz GMBH</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OLV Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rh√∂n-Klinikum Campus Bad Neustadt</name>
      <address>
        <city>Bad Neustadt an der Saale</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien (CCB)</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>German Heart Centre Munich</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Regionale &quot;F. Miulli&quot;</name>
      <address>
        <city>Acquaviva delle Fonti</city>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel&#xD;
for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

